Elicio Therapeutics Inc. CEO Robert Connelly acknowledged “a general malaise about cancer vaccines,” but described the strategy of his firm to BioWorld as “very different. None of these other approaches [has] delivered the goods to the lymph nodes, where the immune response is orchestrated.”
Cambridge, Mass.-based Elicio pulled down $33 million in a series B financing to advance lymph node-targeted immunotherapies that include ELI-002, an Amphiphile KRAS vaccine that takes aim at all seven of the KRAS mutations driving 99% of mutant KRAS cancers – a group estimated to take up 25% of all human solid tumors.
The company has nailed down preclinical validation, toxicology studies and manufacturing. A pre-IND meeting with the FDA went well, and Elicio expects to hear from regulators by mid-November that it can start a phase I/II study in pancreatic cancer patients in the first half of 2020. See http://www.bioworld.com/content/where-action-elicio-33m-series-b-powers-bid-aimed-lymph-cancer for full story.